Knight Therapeutics (KHTRF)
OTHER OTC:KHTRF
Holding KHTRF?
Track your performance easily

Knight Therapeutics (KHTRF) Income Statement

32 Followers

Knight Therapeutics Income Statement

Last quarter (Q2 2024), Knight Therapeutics's total revenue was C$95.57M, an increase of 6.30% from the same quarter last year. In Q2, Knight Therapeutics's net income was C$-1.94M. See Knight Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
C$ 337.87MC$ 328.20MC$ 293.56MC$ 243.48MC$ 199.52MC$ 47.46M
Cost of Revenue
C$ 174.44MC$ 175.55MC$ 155.50MC$ 128.07MC$ 117.83MC$ 20.54M
Gross Profit
C$ 163.43MC$ 152.65MC$ 138.06MC$ 115.41MC$ 81.69MC$ 26.92M
Operating Expense
C$ 155.34MC$ 146.28MC$ 155.12MC$ 128.24MC$ 111.69MC$ 39.58M
Operating Income
C$ 8.10MC$ 6.37MC$ -17.06MC$ -12.83MC$ -30.00MC$ -12.66M
Net Non Operating Interest Income Expense
C$ -193.00KC$ 87.00KC$ 4.03MC$ -3.76MC$ -10.92MC$ -23.17M
Other Income Expense
C$ -24.07MC$ -28.45MC$ 14.39MC$ 15.76MC$ 51.16MC$ 12.27M
Pretax Income
C$ -23.68MC$ -21.99MC$ -58.84MC$ 6.69MC$ 32.09MC$ 22.78M
Tax Provision
C$ -2.46MC$ -5.15MC$ -14.07MC$ -8.98MC$ 325.00KC$ 4.75M
Earnings From Equity Interest Net Of Tax
-----C$ 906.00K
Net Income Common Stockholders
C$ -21.23MC$ -16.84MC$ -44.78MC$ 15.68MC$ 42.07MC$ 14.52M
Basic EPS
C$ -0.20C$ -0.16C$ -0.26C$ 0.13C$ 0.32C$ 0.10
Diluted EPS
C$ -0.21C$ -0.16C$ -0.26C$ 0.13C$ 0.32C$ 0.10
Basic Average Shares
C$ 412.37MC$ 107.47MC$ 114.89MC$ 124.48MC$ 131.78MC$ 139.76M
Diluted Average Shares
C$ 412.17MC$ 107.47MC$ 114.89MC$ 124.52MC$ 131.99MC$ 140.14M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
C$ 329.78MC$ 321.83MC$ 310.62MC$ -256.31MC$ -229.52MC$ -60.12M
Net Income From Continuing And Discontinued Operation
C$ -21.23MC$ -16.84MC$ -44.78MC$ 15.68MC$ 42.07MC$ 14.52M
Normalized Income
C$ -19.24MC$ -17.88MC$ -48.93MC$ -2.72MC$ 22.73MC$ 21.15M
Interest Expense
------
EBIT
C$ -12.13MC$ -9.50MC$ -52.24MC$ 10.31MC$ 35.48MC$ 23.15M
EBITDA
C$ 38.77MC$ 40.90MC$ 10.38MC$ 58.22MC$ 67.56MC$ 27.42M
Currency in CAD

Knight Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis